详细介绍
MLH1抗体 错配修复蛋白1抗体
广州健仑生物科技有限公司
MLH1(MutL protein homolog 1)是一种错配修复蛋白,其基因定位在3号染色体P臂的21.3位上。突变型的错配修复蛋白常表达于高频度微卫星不稳定(MSI-H)患者中,与常染色体的显性遗传相关,也称为遗传性非息肉病性结、直肠癌(HNPCC),也可见于散发性(MSI-H)结、直肠癌患者。MLH1、MSH2、MSH6抗体可用于患者及其家族对该疾病的筛查研究。文献报道高频度微卫星不稳定(MSI-H)的结、直肠癌患者比低频度微卫星不稳定性(MSI-L)及微卫星稳定(MSS)的患者的预后好。
我司还提供其它进口或国产试剂盒:登革热、疟疾、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。
欢迎咨询
欢迎咨询
MLH1抗体 错配修复蛋白1抗体
【产品介绍】
细胞定位:细胞浆/细胞核
克隆号:ES05
同型:IgG
适用组织:石蜡/冰冻
阳性对照:直肠癌
抗原修复:热修复(EDTA)
抗体孵育时间:60min
产品编号 | 抗体名称 | 克隆型别 |
OB160 | Melanoma Associated Antigen(黑色素瘤相关抗原) | KBA.62 |
OB161 | Melanoma(黑色素瘤) | HMB-45 |
OB162 | Mesothelial Cell 间皮细胞 | HBME-1 |
OB163 | MGMT(甲基鸟嘌呤甲基转移酶) | UMAB56 |
OB164 | MHA (髓样/组织细胞抗原) | MAC387 |
OB165 | MLH1(错配修复蛋白1) | ES05 |
OB166 | MPO(髓过氧化物酶) | polyclonal |
OB167 | MSH2(错配修复蛋白2) | G219-1129 |
OB168 | MSH6(错配修复蛋白6) | SP93 |
OB169 | MUC1(粘蛋白1) | MRQ-17 |
OB170 | MUC2(粘蛋白2) | MRQ-18 |
OB171 | MUC5AC(粘蛋白5AC) | MRQ-19 |
OB172 | MUM1(多发性骨髓瘤致癌蛋白) | MRQ-8 |
OB173 | MyoD1(横纹肌肉瘤标志) | EP212 |
OB174 | Myogenin(肌浆蛋白) | F5D |
OB175 | Myoglobin(肌红蛋白) | polyclonal |
OB176 | Myoglobin(肌红蛋白) | MGN01 |
OB177 | Myosin Heavy Chain (Smooth Muscle)肌球蛋白重链(平滑肌)/SMMHC | SMMS-1 |
OB178 | Napsin A(天冬氨酸蛋白酶4) | MRQ-60 |
OB179 | N-Cadherin (钙粘附蛋白-N) | 6G11 |
OB180 | Nestin (巢蛋白) | 10C2 |
MLH1抗体
想了解更多的产品及服务请扫描下方二维码:
【公司名称】 广州健仑生物科技有限公司
【市场部】 欧
【】
【腾讯 】
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-103室
MLH1 (MutL protein homolog 1) is a mismatch repair protein whose gene is located on chromosome 21.3 of P-arm of chromosome 3. Mutant mismatch repair proteins are often expressed in high frequency microsalite instability (MSI-H) patients and are associated with autosomal dominant inheritance, also known as hereditary nonpolyposis colorectal (HNPCC) , Can also be found in sporadic (MSI-H) node, rectal cancer patients. MLH1, MSH2, MSH6 antibodies are useful in screening studies of this disease in patients and their families. It has been reported in the literature that high frequency microsalite instability (MSI-H) nodes and rectal cancer patients have a better prognosis than low frequency microsalite instability (MSI-L) and microsalite stable (MSS) patients.